Bitterroot Bio is a startup based in the United States, most recent round Series A, 1 tracked investor.
Based in the United States, Bitterroot Bio is a startup. Its most recent tracked round is Series A. Brouky records 1 investor associated with the company.
Bitterroot Bio is a biotechnology company focused on developing immunotherapies for cardiovascular disease by targeting the CD47/SIRPα pathway to address atherosclerosis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.